Compare · NVO vs SYRE
NVO vs SYRE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 29.3x SYRE ($6.52B).
- Over the past year, NVO is down 44.3% and SYRE is up 338.4% - SYRE leads by 382.7 points.
- SYRE has been more active in the news (15 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for SYRE).
- Company
- Novo Nordisk A/S
- Spyre Therapeutics Inc.
- Price
- $43.87+2.52%
- $78.76+4.94%
- Market cap
- $191.15B
- $6.52B
- 1M return
- -6.72%
- +4.88%
- 1Y return
- -44.33%
- +338.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 8
- 15
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SYRE
- Spyre Therapeutics Announces Grants of Inducement Awards
- Chief Medical Officer Sloan Sheldon exercised 8,333 shares at a strike of $27.46 and sold $624,975 worth of shares (8,333 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Turtle Cameron sold $1,056,486 worth of shares (15,000 units at $70.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 597,540 units (SEC Form 4)
- Chief Financial Officer Burrows Scott L sold $532,937 worth of shares (7,500 units at $71.06) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $14.50 (SEC Form 4)
- Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
- Spyre Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- SEC Form 4 filed by Director Albers Jeffrey W.
- SEC Form 4 filed by Director Henderson Michael Thomas
- SEC Form 4 filed by Director Stelzer Laurie